Navigation Links
Merz Pharmaceuticals Receives J-Code For Xeomin® (incobotulinumtoxinA)
Date:1/4/2012

GREENSBORO, N.C., Jan. 4, 2012 /PRNewswire/ -- Merz Pharmaceuticals, LLC, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific Healthcare Common Procedure Coding System (HCPCS) billing code, J0588 "INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT" for Xeomin® (incobotulinumtoxinA), effective beginning January 1, 2012.

The U.S. Food and Drug Administration (FDA) approved XEOMIN in July 2010 for the treatment of cervical dystonia in adults, to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients, and blepharospasm in adults who have been previously treated with Botox® (onabotulinumtoxinA).

"We are so pleased that CMS granted a permanent product-specific code for XEOMIN," said Janet Hieshetter, Executive Director of the Dystonia Medical Research Foundation (DMRF). "This milestone reinforces the importance of ensuring access to all available treatment options. The DMRF congratulates Merz on this achievement and applauds their ongoing dedication to patient and physician support."

Merz is committed to supporting patients and physicians in the cervical dystonia and blepharospasm community. In addition to offering services such as the industry-leading Co-pay Assistance Program, which helps alleviate patient out-of-pocket expenses, XEOMIN's list price has been reduced by nearly 20 percent, effective October 6, 2011, in an effort to ensure access to therapy for the greatest number of patients.

XEOMIN is the only botulinum neurotoxin that requires no refrigeration prior to reconstitution and can be stored at room temperature for up to 36 months. XEOMIN is also the only type A botulinum neurotoxin that is available in 50-unit single use vials that may allow for a reduction in wastage and may minimize patient out-of-pocket expenses.

"This is a
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
2. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy
3. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
4. MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Jazz Pharmaceuticals to Hold Investor Conference Call on January 5 to Discuss 2012 Financial Guidance and Azur Pharma Transaction
6. Radient Pharmaceuticals Announces Reverse Stock Split
7. Idenix Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10. Endo Pharmaceuticals to Present at J.P. Morgan 30th Annual Healthcare Conference
11. Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status from the ... is the most common cardiac arrhythmia and has become recognized ... to stroke and possible death. More than 5 million patients ... fibrillation and the numbers are rapidly increasing as the population ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... A novel combination of drugs was,able to completely ... promise for the effective treatment of patients with ... Illinois University,School of Medicine presented the results of ... and pulmonary metastases in female SCID,mice., Paclitaxel ...
... in Breast Cancer -, SAN ANTONIO ... PTC,Therapeutics, Inc. (PTC), a biopharmaceutical company focused ... drugs,targeting post-transcriptional control mechanisms announced the,presentation of ... its novel,internally discovered, vascular endothelial growth factor ...
Cached Medicine Technology:New Drug Combination is Able to Eradicate Breast Metastases in Mice 2PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium 2PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium 3PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium 4
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of the ... (HRV), heart coherence and the physiology of emotions, ... algorithms to chipset manufacturers and consumer electronics companies. ... offer its HRV solutions, tap into its HRV ... normative HRV databases and algorithms for developing consumer ...
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
(Date:12/17/2014)... MONDAY, Dec. 15, 2014 (HealthDay News) -- As gas ... and deaths, a new study suggests. In times ... many of those riders are inexperienced, the researchers explained. ... in California, which has the highest number of motorcycle ... number of motorcyclist deaths. The analysis revealed a ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Poor students get more ... a new study finds. But, the opposite is true ... having fruits and vegetables at school may give a healthy ... But, no matter what the family income level, students all ... the study found. The study was published recently in ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... ... on collaboration - has released a case study about how its innovative HR transformation process ... strategic role, including developing HR leaders. , ... Cambridge, MA (PRWEB) June 23, 2009 -- Interaction Associates (IA) - a 40-year ...
... ... launched his new website, www.LivingwellNewYork.com , to coincide with an exciting new direction he is ... ... has been practicing Chiropractic care in New York City for more than 13 years in ...
... ... technology company, and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, ... a significant price reduction in the cost of liquid culture testing for TB (Tuberculosis). ... Oxford, UK ...
... , MELBOURNE, Australia, June 22 Cytopia Ltd (ASX: CYT) ... Application (IND) with the US Food and Drug Administration (FDA) ... , , Following FDA review, the company intends to ... myelofibrosis, a serious progressive and chronic condition where scar tissue ...
... Stroke Company Exemplifies Firm,s Strategy in the Field of ... 22 Sofinnova Partners of Paris, France today announced ... device company CoAxia. The round also included participation ... Partners, Canaan Ventures Partners, Johnson and Johnson Development Corporation, ...
... PHILADELPHIA, June 22 With yet another tragedy in ... strong regulations to protect residents of our state,s assisted ... outrageous and dangerous practices such as those that forced ... Brightfield assisted living facility. , , Earlier this ...
Cached Medicine News:Health News:Transforming the HR Function Into Strategic Partner at World's Largest Medical Device Company 2Health News:New York City Chiropractor Announces New State-Of-The-Art Facility, Website 2Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Health News:Cytopia Lodges IND for JAK2 Inhibitor CYT387 2Health News:Sofinnova Partners Leads Investment Round in CoAxia 2Health News:Sofinnova Partners Leads Investment Round in CoAxia 3Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 2Health News:Death at Assisted Living Facility Points to Desperate Need for Better Regulations from the State 3
Knife sharpening kit...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... MNL 4404 & 4405 series Freezing Stages ... devices have no moving parts and need only ... water for operation. Freezing starts immediately ... is adjustable so that optimum cutting temperatures can ...
... The autoimmune destruction of the insulin-producing ... a period of time leading to ... mellitus. During this extended pre-clinical phase, ... a variety of islet cell antigens ...
Medicine Products: